Radiation therapy for slow-growing stomach lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether a specific course of focused radiation (20 Gy) can control indolent (slow-growing) lymphoma in the stomach or upper small intestine. It may help shrink or stabilize tumors and lymph node involvement while limiting side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a slow-growing lymphoma starting in the stomach or duodenum
- Your biopsy shows either marginal zone lymphoma or follicular lymphoma
- Your disease is only in stage I or II (not stage III or IV)
- Your blood/medical history suggests H. pylori is negative or the lymphoma is resistant to antibiotics
- You are 18 or older and can give signed consent
- You have adequate overall health for treatment (ECOG 0 to 3)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new computer-assisted radiation therapy approach for early-stage lymphoma (cancer) in the stomach. The AI system helps doctors customize and adjust your radiation treatment in real-time, potentially improving outcomes and reducing side effects.
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
This trial tests a combination of low-dose radiation therapy, immunotherapy, and chemotherapy for people whose stomach or colon cancer has spread to the lining of the belly (peritoneal cavity). The goal is to see if this approach can help control the cancer.
This Phase 2 study tests whether very low-dose radiation (adjusted based on how you respond) can treat marginal zone lymphoma without adding other medicines at first. It may help some people by reducing radiation exposure while still controlling the cancer.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of low-dose radiotherapy, chemotherapy, and an immunotherapy drug (tislelizumab) before and after surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Hear when a new Follicular Lymphoma (Gastric or Duodenal) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.